MAIA Biotechnology Inkomsten in het verleden

Verleden criteriumcontroles 0/6

De winst van MAIA Biotechnology is gedaald met een gemiddeld jaarlijks tempo van -26%, terwijl de winst van de sector Biotechs jaarlijks groeide met 19.3%.

Belangrijke informatie

-26.0%

Groei van de winst

8.3%

Groei van de winst per aandeel

Biotechs Groei van de industrie	17.0%
Inkomstengroei	n/a
Rendement op eigen vermogen	-1,602.6%
Nettomarge	n/a
Laatste winstupdate	30 Sep 2024

Recente prestatie-updates uit het verleden

Geen updates

Recent updates

Opbrengsten en kosten

Hoe MAIA Biotechnology geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.

Inkomsten en omzetgeschiedenis

NYSEAM:MAIA Opbrengsten, kosten en inkomsten (USD Millions )
Datum	Inkomsten	G+A Uitgaven	R&D-uitgaven
30 Sep 24	-26	8	11
30 Jun 24	-28	8	11
31 Mar 24	-24	9	11
31 Dec 23	-20	9	11
30 Sep 23	-18	8	10
30 Jun 23	-18	9	10
31 Mar 23	-16	8	9
31 Dec 22	-16	7	9
30 Sep 22	-15	7	8
30 Jun 22	-15	5	7
31 Mar 22	-15	5	5
31 Dec 21	-13	4	3
30 Sep 21	-13	6	3
31 Dec 20	-7	6	1

Kwaliteitswinsten: MAIA is momenteel verliesgevend.

Groeiende winstmarge: MAIA is momenteel verliesgevend.

Analyse vrije kasstroom versus winst

Analyse van de winstgroei in het verleden

Winsttrend: MAIA is verliesgevend en de verliezen zijn de afgelopen 5 jaar toegenomen met een snelheid van 26% per jaar.

Versnelling van de groei: Het is niet mogelijk om de winstgroei van MAIA over het afgelopen jaar te vergelijken met het gemiddelde over de afgelopen vijf jaar, omdat het bedrijf momenteel verliesgevend is.

Winst versus industrie: MAIA is verlieslatend, waardoor het lastig is om de winstgroei van het afgelopen jaar te vergelijken met die van de Biotechs industrie ( 16.6% ).

Rendement op eigen vermogen

Hoge ROE: MAIA heeft een negatief Return on Equity ( -1602.59% ), omdat het momenteel verliesgevend is.

MAIA Biotechnology Inkomsten in het verleden

Verleden criteriumcontroles 0/6

Belangrijke informatie

Recente prestatie-updates uit het verleden

Recent updates

MAIA Biotechnology Announces Late-Breaking Abstract of THIO-101 Updates Selected for Oral and Poster Presentation at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting

MAIA Biotechnology, Inc. announced that it expects to receive $2.439232 million in funding

MAIA Biotechnology, Inc. to Present New Phase 2 Clinical Trial Data at the H.C. Wainwright 26th Annual Global Investment Conference

New major risk - Financial position

Maia Biotechnology Announces New Updates from Phase 2 Trial of Novel Cancer Treatment Agent

Maia Biotechnology Reveals New Clinical Data Showing Thio’s Strong Efficacy in Non-Small Cell Lung Cancer

New major risk - Share price stability

MAIA Biotechnology, Inc. announced a financing transaction

MAIA Biotechnology, Inc. announced that it expects to receive $0.664994 million in funding

MAIA Biotechnology, Inc., Annual General Meeting, May 24, 2024

MAIA Biotechnology, Inc. announced that it expects to receive $1.327985 million in funding

MAIA Biotechnology, Inc. Appoints Saadettin Kilickap to its Scientific Advisory Board

MAIA Biotechnology, Inc. Announces Positive Efficacy Data for Third-Line Treatment in its Phase 2 THIO-101 Clinical Trial Evaluating THIO Sequenced with CPI Cemiplimab in Advanced NSCLC

MAIA Biotechnology, Inc. Completes Enrollment in THIO-101 Phase 2 Clinical Trial for Non-Small Cell Lung Cancer

MAIA Biotechnology, Inc. has filed a Follow-on Equity Offering in the amount of $1.445 million.

MAIA Biotechnology, Inc. Announces Publication in Nature Communications on Positive Effects of THIO for Potential Treatment of Small Cell Lung Cancer

Maia Biotechnology, Inc. Announces Publication of International Pct Patent Application Covering Anticancer Telomere-Targeting Compounds

MAIA Biotechnology, Inc. Provides Positive Phase 2 Clinical Updates for Lead Anticancer Agent and Outlines Targeted Milestones for 2024

MAIA Biotechnology, Inc. Announces Dose Selection in Thio-101 Phase 2 Clinical Trial for Non-Small Cell Lung Cancer

New major risk - Shareholder dilution

NYSE American Believes MAIA Biotechnology Not in Compliance with Listing Standards

MAIA Biotechnology, Inc. Announces 100% Disease Control in Second-Line Non-Small Cell Lung Cancer Demonstrating Impressive Positive Preliminary Efficacy Data for Ongoing THIO-101 Phase 2 Trial

MAIA Biotechnology, Inc. Reveals New Data Showing THIO's Potent Anticancer Activity in Aggressive Pediatric Brain Cancer

MAIA Biotechnology, Inc. Announces Potent Anticancer Activity of THIO in Gliomas

MAIA Biotechnology, Inc. Announces FDA Clearance of IND Application for THIO, a First-in-Class Telomere Targeting Agent for the Treatment of Non-Small Cell Lung Cancer

MAIA Biotechnology, Inc. (NYSEAM:MAIA) announces an Equity Buyback for $0.8 million worth of its shares.

New major risk - Revenue and earnings growth

MAIA Biotechnology, Inc. Provides Updates for THIO-101 Phase 2 Trial for Non-Small Cell Lung Cancer

MAIA Biotechnology, Inc. Reports Updates on Preliminary Survival Data for Thio-101 Phase 2 Trial for Advanced Non-Small Cell Lung Cancer

MAIA Biotechnology, Inc. Files Second Patent for New Telomere-Targeting Molecules Program

Lead Independent Director recently bought US$300k worth of stock

MAIA Biotechnology, Inc. Announces it Intends to Initiate its Second Phase 2 Go-To-Market Trial Evaluating THIO

MAIA Biotechnology, Inc. Holds Successful Pre-IND Meeting with FDA for Planned US Expansion of THIO-101 Phase 2 Trial for Non-Small Cell Lung Cancer

MAIA Biotechnology, Inc. Expands Phase 2 THIO-101 Trial to Europe

High number of new and inexperienced directors

MAIA Biotechnology, Inc. has completed an IPO in the amount of $10 million.

High number of new and inexperienced directors

Opbrengsten en kosten

Inkomsten en omzetgeschiedenis

Analyse vrije kasstroom versus winst

Analyse van de winstgroei in het verleden

Rendement op eigen vermogen

Rendement op activa

Rendement op geïnvesteerd vermogen

Ontdek sterk presterende bedrijven uit het verleden